MedPath

An observational study of the safety and efficacy of nivolumab as adjuvant treatment for esophageal cancer using the Comprehensive Registry of Esophageal Cancer in the National Clinical Database.

Not Applicable
Recruiting
Conditions
Esophageal cancer or esophagogastric cancer
Registration Number
JPRN-UMIN000050925
Lead Sponsor
Japanese Foundation For Cancer Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
1750
Inclusion Criteria

Not provided

Exclusion Criteria

Cases of esophageal cancer other than squamous cell carcinoma or adenocarcinoma, have not been treated with neoadjuvant therapy, and that resulted in R1 or R2 resection.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath